drugset / Trial / NCT06492655

To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers

NCT06492655

Phase 1 Not yet recruiting 28 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

This is a randomized, open-label, single dose, crossover, phase 1 trial to evaluate the food effect on pharmacokinetic profiles and safety of CKD-383 in healthy volunteers

Timeline

Start
2024-07-04
Primary completion
2024-08-01
Completion
2024-08-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule Oral
Subject Lobeglitazone Small molecule Oral
Subject Metformin Small molecule Oral